- Home
- CRGX vs THFF Comparison
CRGX vs THFF Comparison
Compare CRGX & THFF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- THFF
- Stock Information
- Founded
- CRGX 2021
- THFF 1984
- Country
- CRGX United States
- THFF United States
- Employees
- CRGX N/A
- THFF N/A
- Industry
- CRGX
- THFF Major Banks
- Sector
- CRGX
- THFF Finance
- Exchange
- CRGX Nasdaq
- THFF Nasdaq
- Market Cap
- CRGX 621.4M
- THFF 599.3M
- IPO Year
- CRGX 2023
- THFF N/A
- Fundamental
- Price
- CRGX $13.46
- THFF $47.67
- Analyst Decision
- CRGX Strong Buy
- THFF Hold
- Analyst Count
- CRGX 6
- THFF 1
- Target Price
- CRGX $31.80
- THFF $45.00
- AVG Volume (30 Days)
- CRGX 231.3K
- THFF 42.3K
- Earning Date
- CRGX 03-20-2025
- THFF 02-04-2025
- Dividend Yield
- CRGX N/A
- THFF 4.28%
- EPS Growth
- CRGX N/A
- THFF N/A
- EPS
- CRGX N/A
- THFF 3.68
- Revenue
- CRGX N/A
- THFF $190,119,000.00
- Revenue This Year
- CRGX N/A
- THFF N/A
- Revenue Next Year
- CRGX N/A
- THFF $11.39
- P/E Ratio
- CRGX N/A
- THFF $12.94
- Revenue Growth
- CRGX N/A
- THFF N/A
- 52 Week Low
- CRGX $10.91
- THFF $34.58
- 52 Week High
- CRGX $33.92
- THFF $51.87
- Technical
- Relative Strength Index (RSI)
- CRGX 47.00
- THFF 56.86
- Support Level
- CRGX $12.51
- THFF $46.45
- Resistance Level
- CRGX $15.75
- THFF $47.81
- Average True Range (ATR)
- CRGX 1.09
- THFF 1.09
- MACD
- CRGX 0.17
- THFF 0.35
- Stochastic Oscillator
- CRGX 52.74
- THFF 97.29
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.
About THFF First Financial Corporation Indiana
First Financial Corp operates as a financial holding company, which is engaged in the provision of financial services in the United States. The company offers a wide variety of financial services including commercial, mortgage, and consumer lending, lease financing, trust account services, depositor services, and insurance services, through its subsidiaries. Its primary source of revenue is derived from loans to customers and investment activities.